conflicts of interest to report.

Slides:



Advertisements
Similar presentations
December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
Advertisements

Unbiased Longitudinal Processing of Structural MRI in FreeSurfer Martin Reuter
Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.
Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
ADNI 3 Clinical Core Plans
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects Liana G. Apostolova, Amity E. Green, Kristy S. Hwang, Jonathan.
Dept. of Radiology, Xuanwu Hospital, Capital Medical University Beijing: Emeil: 首都 Update of China-ADNI Kuncheng Li.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Alzheimer’s Society, UK Our research programme
Ongoing BIRN-GCRC Collaborations Medical College Wisconsin (non BIRN site) –Functional MRI acquisition calibration University of Texas (non BIRN site)
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.
Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.
Neuroimage Analysis Center An NCRR National Resource Center Time Series MRI Core Analysis, Modeling - toward Dynamic Surrogates.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease: A Magnetic Resonance Imaging Study Bartzokis, et al. UCLA.
Structural MRI as a Biomarker of Disease Progression in AD Department of Diagnostic Radiology and MRI Research Lab Presented by Clifford Jack, M.D. at.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Sven Haller Haller, Nguyen, Rodriguez, Emch, Gold, Bartsch, Lovblad, Giannakopoulos.
Normal Pressure Hydrocephalus
MR SPECTROCOPY AND MRI TO MEASURE TREATMENT OF NEURODEGENERATION MICHAEL W. WEINER Professor of Radiology, Medicine, Psychiatry, and Neurology, U.C.S.F.
Submitted by :- Sridev Shyam K.V. Problem Definition.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.
INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Volume 3, Issue 4, Pages (November 2017)
Deborah Jiang Kristy S. Hwang Yvette Bordelon Liana G. Apostolova
Metabolic Syndrome and Progression of Mild Cognitive Impairment
Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Moving from Detection to Pre-detection of Alzheimer’s Disease from MRI Data K A N N P Gunawardena.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Mohammad Kassir, PGY4, R3 September 15th, 2016
The BrainHealthRegistry
COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE   Mirjana Babić Leko1, Matea Nikolac Perković2,
Imaging biomarkers of post-stroke prognosis
Differentiating Normal Pressure Hydrocephalus from Alzheimer Disease and Healthy Controls: Sulcal Depth Alexander M. Le, M.S., Benjamin Ades-Aron, M.S.,
Volume 2, Issue 1, Pages (January 2016)
conflicts of interest to report.
ADI Disease International 7-10 March, 2012
Early Cognitive Decline and the Aging Brain - Overview
Keith A. Josephs, MD, MST, MSc  Mayo Clinic Proceedings 
Early Dementia Distinguishing AD From MCI
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Volume 10, Issue 3, Pages (January 2015)
Identifying and validating biomarkers for Alzheimer's disease
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
Identifying and validating biomarkers for Alzheimer's disease
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Biomarker Modeling of Alzheimer’s Disease
The Generality of Parietal Involvement in Visual Attention
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.
Ongoing Research With Vascular Risk Factors and the RAS in Individuals at Risk for AD Whitney Wharton, PhD Assistant Professor,
Presentation transcript:

conflicts of interest to report. Conflict of Interest Disclosure Amanda F. Khan, MSc. Medical Biophysics Has no real or apparent conflicts of interest to report. I have no conflict of interests to report.

Ventricle Sub-Region Segmentation Utilizing MRI as a Structural Biomarker of Alzheimer’s Disease Amanda F. Khan Department of Medical Biophysics Imaging Research Laboratories Robarts Research Institute The University of Western Ontario Supervisors: Dr. Michael Borrie, Dr. Robert Bartha Alzheimer’s Disease International – March 28th, 2011

The Ventricular System Lateral ventricles structures containing CSF in the midbrain atrophy of surrounding tissues leads to increase in CSF volume increase in CSF = increase in lateral ventricles (surrogate measure) capture this increase on MRI, sometimes years before cognitive decline can be measured 3D image adapted from: The Biodidac

Atrophy as Captured on MRI Normal AD Images adapted from: The Alzheimer's Disease Research Center, Florida

NIH: AD Biomarker Criteria Development of Specific AD Treatment Strategies Requires Ventricular Enlargement as a Biomarker 1 Dx in early stages when intervention is most effective Can detect very early brain atrophy before cognitive decline can be measured 2 Treatment efficacy can be monitored Serial MRI can measure atrophy (or lack thereof) over time in clinical trials in a way cognitive tests cannot Source: NIH -Ways Towards an Early Diagnosis in Alzheimer’s Disease

Hypothesis That sub-region ventricular volume expansion, particularly that of the temporal horns, may be a more sensitive biomarker of disease progression than total ventricular volume Normal Elderly Control AD Patient

Alzheimer’s Disease Neuroimaging Initiative ADNI 6 year multi-site study of NEC, MCI & AD 55 participating sites imaging, clinical + cognitive measures, biological samples MRI 1.5T (T1 –weighted) MP-RAGE pulse sequence Source of Map: The Alzheimer’s Disease Neuroimaging Initiative

Methods Baseline Month 12 Month 24 97 subjects total blinded segmentation lateral ventricle volumes extracted with software NEC n=26 MCI n=42 AD n=29

Brain Ventricle Quantification (BVQ)

Ventricle Sub-Regions Left and Right Hemispheres Ventricle Sub-Region Lateral Ventricle lateral anterior (LA) lateral middle (LM) lateral posterior (LP) Temporal Horn anterior horn (AH) posterior horn (PH)

Preliminary Statistical Analysis Procedure Data Used Evaluate Repeated-measures ANOVA Conducted on each sub-region over the 3 time periods Sub-region volume longitudinal significance Paired t-tests Post-hoc analysis to ANOVAs Pair-wise significance between any two time points

Normal Elderly Controls (NEC) Temporal Horn Sub-Region Significant? Type of Pairwise Significance LPH YES Baseline and M24 Superior view of lateral (shades of red) and temporal horn (green) regions

Mild Cognitive Impairment (MCI) Temporal Horn Sub-Region Significant? Type of Pairwise Significance LAH, RAH, LPH, RPH YES Baseline and M24 Superior view of lateral (shades of red) and temporal horn (green) regions

Alzheimer’s Disease (AD) Temporal Horn Sub-Region Significant? Type of Pairwise Significance LAH, RAH, LPH, RPH YES Baseline and M24 Superior view of lateral (shades of red) and temporal horn (green) regions

Total Ventricle vs. Horn Volume Normal controls: NO significant temporal horn enlargement

Calculated Sample Sizes Estimated sample size required to detect a 25% reduction in the mean annual rate of atrophy in a two-sided test with α=0.05 for a two-arm study over one year Measure Patient Classification Calculated n Number Temporal Horn Only AD 284 Total Ventricle 226 MCI 1547 420 ADAS-cog 3237 2066 Equation source: The ADNI Biostatistics Core

Summary NEC  AD more sub-regions show significant growth in more pair-wise comparisons MCI & AD significant enlargement in temporal horns, NEC do not Temporal horn: discriminate patients based on normal age-related atrophy and AD Smaller sample sizes for total ventricle than horn volumes but significantly smaller for both measures compared to ADAS-cog

Acknowledgements Supervisors: Sources of Funding and Collaboration: Dr. Robert Bartha Dr. Michael Borrie Collaborators: Matthew Smith Yun-Hee Choi Support: Michael Marynowski Henry Betta Vaishali Karnik Sources of Funding and Collaboration: